KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Recursion Pharmaceuticals (RXRX) Return on Equity (2021 - 2025)

Historic Return on Equity for Recursion Pharmaceuticals (RXRX) over the last 5 years, with Q3 2025 value amounting to 0.73%.

  • Recursion Pharmaceuticals' Return on Equity fell 500.0% to 0.73% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.73%, marking a year-over-year decrease of 500.0%. This contributed to the annual value of 0.62% for FY2024, which is 700.0% up from last year.
  • As of Q3 2025, Recursion Pharmaceuticals' Return on Equity stood at 0.73%, which was down 500.0% from 0.7% recorded in Q2 2025.
  • Over the past 5 years, Recursion Pharmaceuticals' Return on Equity peaked at 0.44% during Q1 2021, and registered a low of 0.82% during Q1 2024.
  • In the last 5 years, Recursion Pharmaceuticals' Return on Equity had a median value of 0.59% in 2023 and averaged 0.53%.
  • As far as peak fluctuations go, Recursion Pharmaceuticals' Return on Equity plummeted by -8400bps in 2022, and later surged by 2400bps in 2025.
  • Over the past 5 years, Recursion Pharmaceuticals' Return on Equity (Quarter) stood at 0.32% in 2021, then crashed by -76bps to 0.56% in 2022, then fell by -29bps to 0.73% in 2023, then rose by 18bps to 0.59% in 2024, then dropped by -22bps to 0.73% in 2025.
  • Its Return on Equity stands at 0.73% for Q3 2025, versus 0.7% for Q2 2025 and 0.58% for Q1 2025.